ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Renal Dysfunction at 12 Months Is Not Associated with Everolimus Exposure in De Novo Renal Transplant Recipients.

F. Shihab,1 Y. Qazi,2 S. Mulgaonkar,3 K. McCague,4 D. Patel,4 V. Peddi,5 D. Shaffer.6

1University of Utah, Salt Lake City, UT
2University of Southern California, Los Angeles, CA
3Barnabas Health, West Orange, NJ
4Novartis Pharmaceuticals Corporation, East Hanover, NJ
5California Pacific Medical Center, San Francisco, CA
6Vanderbilt University, Nashville, TN.

Meeting: 2016 American Transplant Congress

Abstract number: B135

Keywords: Glomerular filtration rate (GFR), Kidney transplantation, Renal dysfunction

Session Information

Session Name: Poster Session B: Drug Minimization

Session Type: Poster Session

Date: Sunday, June 12, 2016

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Renal dysfunction at 1 year post-transplantation is associated with poor graft outcome. Here, we assess post-transplant renal function associated with everolimus (EVR) and tacrolimus (TAC) exposure at 12 months in a Phase IIIb, multi-center, randomized, open-label non inferiority study (US92).

De novo renal transplant recipients (n=309) received EVR 0.75 mg b.i.d. as starting dose, adjusted to maintain a trough level of 3–8 ng/mL. Patients received TAC and prednisone per local guidelines, with TAC dosing adjusted to achieve trough levels of 4–7 ng/mL (0–2 Months [M]), 3–6 ng/mL (2–6 M) and 2–5 ng/mL (6–12 M). At 12 months, incidences of low estimated glomerular filtration rate (eGFR; <30 mL/min/1.73 m2), decreased eGFR (decrease in eGFR by 30% compared to month 1), and proteinuria (urinary protein:creatinine ratio of ≥500 mg/g) were assessed to evaluate the relationship between renal dysfunction and time-normalized EVR and TAC exposure.

Measures of low eGFR and decreased eGFR were more frequent in patients with higher concentrations of TAC, but were not associated with increasing EVR concentrations (Table 1, n=306). The incidence of proteinuria correlated independently with both increasing EVR and TAC concentrations.

These results demonstrate that rates of low eGFR and decreased eGFR were higher with increased TAC concentrations, but not with increased EVR concentrations, at 12 months in de novo renal transplant recipients. Proteinuria was more frequent with increasing TAC and EVR concentrations.

Table 1: n/N, (%) Low eGFR Decreased eGFR Proteinuria (≥500 mg/g)
Total incidence 27/306 (8.8) 55/306 (18.0) 69/306 (22.5)
Everolimus (ng/ml)      
<3 2/21 (9.5) 3/21 (14.3) 4/22 (18.2)
3–<6 21/206 (10.2) 44/204 (21.6) 46/206 (22.3)
6–<8 3/62 (4.8) 6/62 (9.7) 15/59 (25.4)
8–<12 0/9 (0.0) 2/12 (16.7) 4/12 (33.3)
≥12 1/1 (100.0) 0 0
Tacrolimus (ng/ml)      
<2 0/2 (0.0) 0/2 (0.0) 0/2 (0.0)
2–<5 5/98 (5.1) 9/93 (9.7) 11/96 (11.5)
5–<8 19/178 (10.7) 43/184 (23.4) 52/178 (29.2)
≥8 3/21 (14.3) 3/20 (15.0) 6/23 (26.1)

CITATION INFORMATION: Shihab F, Qazi Y, Mulgaonkar S, McCague K, Patel D, Peddi V, Shaffer D. Renal Dysfunction at 12 Months Is Not Associated with Everolimus Exposure in De Novo Renal Transplant Recipients. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Shihab F, Qazi Y, Mulgaonkar S, McCague K, Patel D, Peddi V, Shaffer D. Renal Dysfunction at 12 Months Is Not Associated with Everolimus Exposure in De Novo Renal Transplant Recipients. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/renal-dysfunction-at-12-months-is-not-associated-with-everolimus-exposure-in-de-novo-renal-transplant-recipients/. Accessed May 31, 2025.

« Back to 2016 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences